Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2019 Q1- Text added to 2019 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
New words:
adalimumab, agonist, AMPLE, Anagni, armed, blinded, burden, called, caption, Catalent, cellular, central, certiorari, conducted, conversion, cutoff, Dana, decree, display, divest, earliest, esophageal, exploring, Farber, featured, free, FTC, GBM, HCC, Hematology, implementing, indirect, interfere, interval, Italy, judge, longest, mechanistic, metatstatic, molecular, numerically, oncolytic, Otezla, paediatric, petition, poster, predict, QoL, radiation, rank, redeemable, requisite, retail, rheumatoid, Rheumatology, Sequential, seropositive, solid, sorafenib, STING, symptom, temozolomide, tendered, trustee, unpaid, unwound, validly, violate, wholly, window
Valuein 2019 Q1 filing- Value in 2019 Q2 filing
Original filings
Filing view